In chronic myeloid leukemia (CML) cell lines, brief exposure to pharmacologically relevant dasatinib concentrations results in apoptosis. In this study, we assess the impact of intensity and duration of Bcr-Abl kinase inhibition on primary CD34 þ progenitors of chronic phase CML patients. As CML cells exposed to dasatinib in vivo are in a cytokine-rich environment, we also assessed the effect of cytokines (six growth factors cocktail or granulocyte-macrophage colonystimulating factor (CSF) or granulocyte-CSF) in combination with dasatinib. In the presence of cytokines, short-term intense Bcr-Abl kinase inhibition (X90% p-Crkl inhibition) with 100 nM dasatinib did not reduce CD34 þ colony-forming cells (CFCs). In contrast, without cytokines, short-term exposure to dasatinib reduced CML-CD34
Introduction
Chronic myeloid leukemia (CML) is characterized by the BCR-ABL1 fusion oncogene. 1 Constitutive tyrosine kinase activity is central to the ability of BCR-ABL1 to transform hematopoietic cells both in vitro and in vivo. 2, 3 Imatinib mesylate (IM; Glivec, Novartis Pharmaceutical, Basel, Switzerland), a small molecule tyrosine kinase inhibitor (TKI), is the first line of treatment for newly diagnosed chronic phase CML (CML-CP) patients. Although 87% of newly diagnosed CML-CP patients achieve complete cytogenetic response (CCR) after 5 years of IM treatment, only a minority of patients achieve complete molecular response (CMR). 4 Moreover, 50% of patients who were in CMR for 2 years relapsed within 6 months of discontinuing IM treatment, 5 indicating that the majority of the CML-CP patients are not cured by IM treatment. Bocchia et al. 6 also reported persistence of leukemic progenitor cells in patients who have achieved CCR with IM treatment. In agreement with this, in vitro data showed that IM, nilotinib and dasatinib have antiproliferative effects on CD34 þ leukemic progenitor cells, but are not able to eradicate quiescent leukemic progenitors. [7] [8] [9] [10] [11] Thus, clinical studies as well as in vitro studies show that leukemic early progenitors are refractory to TKI and may be responsible for long-term persistence and resistance of these cells during IM treatment. Refractoriness of leukemic progenitor cells to TKIs has been postulated to be due to inadequate Bcr-Abl kinase inhibition. 7 But more potent second-generation TKIs, which inhibit Bcr-Abl kinase more effectively, 7, 12, 13 do not result in increased efficacy in reducing nondividing CML progenitors. 7, 14 Hence it is necessary to understand Bcr-Ablindependent mechanism of TKI resistance.
Le Coutre et al. 15 reported that 20-21 h in vitro exposure to 1 mM IM is required to induce cell death and inhibit proliferation of BCR-ABL1 þ KU812 and MC3 cell lines. Moreover, daily dosing of IM in mice did not eradicate the CML cells, whereas an 8-h schedule eradicated it and increased disease-free survival. 15 Subsequent clinical pharmacokinetic and pharmacodynamic studies of IM showed significant responses with trough blood levels above 1 mM. 16, 17 These results set the paradigm for continuous Bcr-Abl kinase inhibition by IM as the optimal strategy in CML therapy. Dasatinib is a second-generation dual (Bcr-Abl and Src) kinase inhibitor that is effective in IM-resistant patients. 18 Dasatinib has a short half-life of 3-5 h in vivo and there is a near-complete reactivation of Bcr-Abl kinase by 8 h after drug administration in CML patients. 13 Despite the short half-life, patients on the recently approved single daily dose of 100 mg dasatinib achieved similar cytogenetic and molecular responses as patients on twice a day dosing (dasatinib 50 mg BD). 19 Recent in vitro data showed that short-term intense Bcr-Abl kinase inhibition is sufficient to induce cell death in BCR-ABL1 þ cell lines. 13, 20, 21 However, most of the CML cell lines are derived from blast crisis patients and do not reflect the CML-CP. Snead et al. 20 recently published the effect of acute potent Bcr-Abl kinase inhibition on CML-CD34 þ cells. However, this study was based on only three CML-CP patient samples. Although leukemic progenitors live in cytokine-enriched microenvironment, this study did not assess the effect TKI in the presence of cytokines.
In this study, we assessed the effect of intense Bcr-Abl kinase inhibition with and without additional cytokines on cell death induced in primary CML-CD34 þ progenitors. Given the prosurvival signaling provided by cytokines we also assessed the effect of concomitant Bcr-Abl and Janus kinase (Jak) inhibition on survival of primary CML-CD34 þ progenitors.
Materials and methods

Cell lines
The BCR-ABL1-expressing (K562) and BCR-ABL1-negative cell lines (HL-60) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and were cultured as previously described. 22 
Patient samples
Blood was collected from CML-CP patients at presentation to the Royal Adelaide Hospital Haematology clinic. All samples were collected with informed consent, before IM therapy. Mononuclear cells were isolated using Lymphoprep (Axis-Shield PoC As, Oslo, Norway) density gradient centrifugation. CD34 þ progenitor cells were isolated by magnetic-assisted cell sorting (Miltenyi Biotech, Bergisch Gladbach, Germany) and the purity was checked by staining cells with anti-CD34-PE (BD Biosciences, San Jose, CA, USA). CD34 þ cells were cultured in serum-deprived medium (SDM), containing Iscove's Modification of Dulbecco Medium (SigmaAldrich, Castle Hill, NSW, Australia) supplemented with 1% bovine serum albumin (Sigma Aldrich), 1 U/ml insulin (Actrapid, Novo Nordisk Pharmaceuticals Pty Ltd, BAULKHAM HILLS, NSW, Australia), 200 mg/ml transferrin (StemCell Technologies, Vancouver, BC, Canada), 10 mg/ml low-density lipoproteins (Sigma Chemicals) and 0.1 mM 2-mercaptoethanol (Sigma Chemicals). In some experiments, SDM was further supplemented with six growth factors (6-GFs) including 10 ng/ml of Flt3-ligand (Immune, Seattle, WA, USA), stem cell factor, interleukin (IL)-3, IL-6, granulocyte colony-stimulating factor (G-CSF) and thrombopoietin. All growth factors except Flt-3 ligand were purchased from PeproTech (Rocky Hill, CT, USA).
TKI
Dasatinib was kindly provided by Bristol-Myers Squibb (New Brunswick, NJ, USA). IM (Glivec) was kindly provided by Novartis Pharmaceuticals. Janus protein TKI (JAK inhibitor-I (JAKI)) and Src inhibitors, SU6656 and PP1, were purchased from Calbiochem (EMD chemicals, Darmstadt, Germany).
Signaling analysis
Western blot analysis for p-Crkl, a surrogate marker of Bcr-Abl kinase activity, was performed as previously described. 23 p-STAT5 (BD Biosciences) signaling was also analyzed by flow cytometry.
Cell death assessment BCR-ABL1
þ cell lines (2 Â 10 5 cells) were cultured with dasatinib or IM, either for a short term (cells were cultured with dasatinib or IM for 30 min and, after thorough drug washout (three washes with warm RPMI media), cells were recultured in drug-free media for a total of 72 h), or long term for 72 h (cells were washed after 30 min of culture with dasatinib or IM and recultured in dasatinib or IM for a total of 72 h). Cell death was assessed by flow cytometry using PE Annexin V (BD Biosciences) and trypan blue staining. CD34 þ cells were cultured in SDM with 0, 10 or 100 nM dasatinib for a short term or long term in the presence or absence of 6-GFs, granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF for 72 h. To assess the effect of IM, CML-CD34 þ cells were cultured with 0, 2 or 30 mM IM for a short term or long term in the presence or absence of 6-GFs for 72 h. On day 4, cell viability was assessed by trypan blue exclusion.
CFU-GM assay
To assess the effect of concomitant cytokines and short-term or long-term dasatinib or IM on colony-forming cells (CFCs), CML-CD34 þ cells were cultured in SDM with or without dasatinib/ IM and JAKI in the presence or absence of cytokines (6-GFs, GM-CSF or G-CSF). After 72 h of culture, viable CD34 þ cells were plated for CFU-GM assay in MethoCult-H4230 (StemCell Technologies) along with five growth factors (20 ng/ml of GM-CSF, IL-3, IL-6, FLT-3 ligand and 50 ng/ml of stem cell factor) in all culture conditions, but without dasatinib or IM. CFU-GM colonies were counted after 14 days.
To assess the effect of cytokine rescue, CML-CD34 þ cells were cultured with dasatinib for 30 min without cytokines, and after thorough drug washout, cells were recultured in dasatinibfree media along with cytokines (GM-CSF or 6-GFs) for 72 h. After 72 h, live cells were plated for CFU-GM assay.
Results
Short-term culture with 100 nM dasatinib inhibits X95% Bcr-Abl kinase in primary CML-CD34
þ progenitor cells
The effect of dasatinib or IM on Bcr-Abl kinase activity was assessed by measuring the decrease in phospho-Crkl (p-Crkl; a surrogate marker of Bcr-Abl kinase activity). Initially, K562 cells were cultured with increasing concentrations of dasatinib or IM for up to 2 h to assess the kinetics of Bcr-Abl kinase inhibition. A 30-min culture with 100 nM dasatinib resulted in X90% p-Crkl inhibition (Supplementary Figure S1 ). More importantly, in primary CML-CD34 þ progenitor cells, 30 min of culture with 100 nM dasatinib (n ¼ 13) or 30 mM IM (n ¼ 7) resulted in 97 ± 3% and 96 ± 4% inhibition of p-Crkl, respectively (Figures 1a-b). Although plasma concentration of 100 nM dasatinib can be achieved therapeutically, 13, 24 30 mM IM (equipotent to 100 nM dasatinib) is 15-20 times higher than the therapeutically achievable concentration of IM. Lower concentrations of dasatinib (10 nM; n ¼ 11) or therapeutically achievable concentration of IM (1-2 mM, n ¼ 7) inhibited p-Crkl by 64 ± 12 and 50±9% in CD34 þ cells, respectively (Table 1 , Figures 1a and b ). These results show that the Bcr-Abl kinase activity of primary CML-CD34 þ progenitor cells can be inhibited by X90% at therapeutically achievable concentrations of dasatinib, but not of IM.
In vivo, dasatinib has a short half-life and there is nearcomplete reactivation of Bcr-Abl kinase activity within 8 h of dosing. 13 To assess the kinetics of Bcr-Abl kinase reactivation in vitro, CML-CD34 þ cells were cultured with 10 or 100 nM dasatinib for 30 min, and after thorough drug washout, cells were recultured in drug-free media for 30 min. Within 30 min of drug washout, 67 ± 10% (n ¼ 5) of p-Crkl was reactivated (Figures 1c and d) . We analyzed p-Crkl reactivation over a longer period in a single patient with adequate cell numbers and showed that X90% p-Crkl reactivated within 8 h of dasatinib washout (data not shown). Similarly, X90% p-Crkl was reactivated within 4 h of dasatinib or IM washout in a CML cell line (Supplementary Figure S2) . Together these results show that there is almost complete reactivation of Bcr-Abl kinase within 4-8 h of drug washout ( Figure 1 and Supplementary Figure S2 ).
In the absence of cytokines, short-term intense Bcr-Abl kinase inhibition triggers cell death in CML-CD34 (Figures 2a and b) . Similarly, long-term partial (10 nM dasatinib or 2 mM IM) or intense (100 nM dasatinib or 30 mM IM) Bcr-Abl kinase inhibition in the absence of cytokines also triggered cell death (Figures 2c and d) and reduced CFC by 70-80% of control (Figures 2a and b) . Thus, in primary CML-CD34 þ progenitor cells, in the absence of growth factors, short-term intense kinase inhibition is sufficient to trigger cell death.
CML progenitor cells live in a cytokine-enriched microenvironment, which have potent survival-promoting activities. Such cytokine milieu may abrogate the ability of dasatinib or IM to eradicate CML progenitors leading to persistence of minimal residual disease. We therefore tested the effect of hematopoietic cytokines on cell death induced by IM and dasatinib on CML-CD34 þ progenitor cells. In the presence of 6-GFs (n ¼ 10), GM-CSF (n ¼ 11) or G-CSF (n ¼ 4), short-term culture with 100 nM dasatinib reduced CFC by only 24, 32 or 5% (Figure 2a) , respectively, despite X90% of p-Crkl inhibition. This is in contrast to 70-80% reduction in CFC with short-term culture with 100 nM dasatinib in the absence of cytokines. In the presence of 6-GFs (n ¼ 10), GM-CSF (n ¼ 11) and G-CSF (n ¼ 4), long-term culture with 100 nM dasatinib reduced CFC by 76, 63 and 59% of no-drug control, respectively (Figure 2a) . Consistent with the results seen with dasatinib, short-term culture with 30 mM IM (n ¼ 3) in the presence of 6-GFs reduced CFC by only 38%, in contrast to 97% reduction in CFC in the absence of cytokines (Figure 2b) . Together, these results suggest that in the presence of cytokines intense Bcr-Abl kinase inhibition is not sufficient to eradicate CML progenitors, and that cytokines provide Bcr-Abl-independent pathway for resistance. 
Jak kinase inhibition abrogates the rescuing effect of cytokines on cell death induced by Bcr-Abl kinase inhibition
Our results raise the possibility that the presence of GM-CSF, G-CSF and 6-GFs promote CML cell survival through signaling pathways that are not targeted by dasatinib. To examine this possibility, we assessed the effect of short-term 100 nM dasatinib on p-STAT5 signaling in CML-CD34 þ cells, in the presence and absence of GM-CSF, G-CSF or 6-GFs (n ¼ 4). STAT5 was constitutively phosphorylated in CML-CD34 þ cells, and in the absence of cytokines, short-term culture with 100 nM dasatinib significantly (P ¼ 0.003) reduced STAT5 phosphorylation (Figures 3a and e) . However, in the presence of 6-GFs (P ¼ 0.9) or GM-CSF (P ¼ 0.6), short-term culture with 100 nM dasatinib did not inhibit STAT5 phosphorylation (Figures 3b, c  and e) . To inhibit the effect of cytokines that transduce their signals through JAK kinases associated with their receptors, we use the JAKI. The combination of 100 nM dasatinib and JAKI significantly reduced p-STAT5 even in the presence of 6-GFs (P ¼ 0.02) or GM-CSF (P ¼ 0.008; Figures 3b-c and e) .
The results shown in Figures 2 and 3 raised the possibility that simultaneous inhibition of Bcr-Abl kinase and cytokine signaling may be more effective in inducing apoptosis in primary CML progenitor cells refractory to dasatinib-mediated cell death, because of the presence of survival-promoting cytokines. To test this possibility further, primary CML-CD34 þ progenitor cells were cultured with 100 nM dasatinib (short-term or long-term) alone or together with JAKI, and survival of CML progenitors was assessed.
Compared with D100ST alone, combination of JAKI and D100ST induced more cell death (Figure 4c ) and reduced CFC, even in the presence of GM-CSF (68.33 ± 14.9 vs 32.35 ± 5.16; n ¼ 4) or G-CSF (94.68 ± 21.12 vs 58.13 ± 13; n ¼ 4; Figure 4a) . Similarly, compared with D100LT alone, combination of D100LT and JAKI induced more cell death (Figure 4d ) and reduced CFC, in the presence of GM-CSF (37.49±7.64 vs 5.76 ± 1.20; n ¼ 4) or G-CSF (41.60 ± 4.4 vs 16.56 ± 6.6; n ¼ 4; Figure 4b ). However, in the absence of hematopoietic cytokines, JAKI did not enhance the effect of 100 nM dasatinib either in short-term (32.45±7.91 vs 41.20±6.70, n ¼ 4; Figure 4a ) or in long-term culture (18.19 ± 4.61 vs 12.90 ± 3.58; n ¼ 4; Figure 4b ). These results show that hematopoietic cytokines can render primary CML-CD34 þ progenitor cells refractory to TKI-mediated cell death. Importantly, the combination of dasatinib and Jak inhibition is able to overcome this cytokinemediated resistance.
Commitment to cell death following short-term intense Bcr-Abl kinase inhibition can be rescued by subsequent GFs and kinase reactivation As shown in Figure 2 , in the absence of cytokines, short-term intense kinase inhibition triggered cell death and reduced CFC by 70-80%. This suggests that in the absence of cytokines, commitment to cell death may occur within 30 min of intense Bcr-Abl kinase inhibition. To examine whether the cell death commitment of CML-CD34 þ progenitors can be reversed by subsequent cytokine supplementation, CML-CD34 þ cells (n ¼ 6) were first cultured with short-term 100 nM dasatinib in the absence of growth factors, after which 6-GFs or GM-CSF were added to the culture for the remaining of 72 h. Under these conditions, 48 and 65% of CFCs were rescued by subsequent supplement of 6-GFs or GM-CSF, respectively (compared with no-drug control, Figure 5a ). These data suggest Induction of apoptosis in primary CML progenitors DK Hiwase et al that cytokine supplementation following short-term intense kinase inhibition rescues 50-60% CML-CD34 þ progenitors. The magnitude of the response varied between patients, as illustrated for CML1 and CML13 profiles (Figure 5b ). This variability suggests a level of heterogeneity across CML-CP patients with regard to cytokine responsiveness. These data also suggest that in some cells commitment to cell death following short-term intense kinase inhibition can be reversed by subsequent cytokine stimulation.
Discussion
Refractoriness of leukemic progenitor cells to TKIs has been postulated to be due to inadequate Bcr-Abl kinase inhibition, 7 possibly due to increased expression of ABCB1 25, 26 and ABCG2 25, 27 efflux proteins, or the quiescent state of leukemic progenitors. [7] [8] [9] However, CML progenitors may use cell survival pathways that are independent of Bcr-Abl kinase activity. 28 Our results indicate that, despite intense Bcr-Abl kinase inhibition, Induction of apoptosis in primary CML progenitors DK Hiwase et al cytokine-enriched short-term culture with 100 nM dasatinib was unable to eradicate the majority of leukemic progenitors, in contrast to cell culture in the absence of cytokines. This is clinically relevant, as the in vivo dasatinib half-life is 3-5 h, and dasatinib is usually administered on a once-a-day dose schedule. Konig et al.
14 showed that nilotinib, in spite of its more potent Bcr-Abl kinase inhibition in CML-CD34 þ cells as compared with IM, did not have increased efficacy in reducing nondividing CML progenitors. Thus, our results and those of others suggest that more potent TKIs by themselves may not be adequate to eliminate CML progenitors that reside within a cytokine-rich microenvironment. Hence, additional factors associated with the maintenance of CML progenitors need to be identified.
We focused on assessing the contribution of cytokine signaling to protect CML progenitors in the presence of BcrAbl inhibitors. Wang et al. 29 showed that adaptive autocrine and paracrine secretion of GM-CSF mediated BCR-ABL1-independent IM and nilotinib resistance through activation of the antiapoptotic Jak-2/STAT5 pathway. In this study, short-term dasatinib inhibited p-STAT5 in CML-CD34 þ cells in the absence of cytokines but not in the presence of GM-CSF or 6-GFs. The combination of Jak inhibition and dasatinib dramatically reduced the phosphorylation of STAT5, despite the cells being cultured in cytokine-enriched media. Konig et al. also reported that nilotinib 14 and dasatinib 12 inhibited MAPK, Akt and STAT5 phosphorylation in CML-CD34 þ cells in the absence, but not in the presence, of growth factors.
In our study, the signaling data were consistent with the results observed in the CFU-GM assay. In the presence of GM-CSF or G-CSF, the combination of a Jak inhibitor and dasatinib reduced cell viability and CFC compared with no-drug control and dasatinib alone. The effect of combined Jak inhibition and dasatinib was more evident when cells were cultured with shortterm dasatinib, but similar findings were also observed in longterm dasatinib culture. When cells were cultured in cytokinefree media, the combination of Jak inhibition and dasatinib did not provide additional benefit over short-term or long-term culture with dasatinib alone. Wang et al. 29 also reported that inhibition of Jak-2 overcomes GM-CSF-induced IM and nilotinib resistance in progenitor cells. Chu et al. 30 reported that suppression of primary CML progenitor growth by IM is associated with enhanced MAPK signaling, which is growth factor dependent. Combined suppression of Bcr-Abl kinase activity and MAPK signaling enhanced inhibition of CML progenitor growth. In our study, the combination of 6-GFs induced higher dasatinib resistance followed by GM-CSF and G-CSF. Dasatinib inhibited p-STAT5 in the presence of G-CSF ( Figure 3) ; however, G-CSF-induced dasatinib resistance was still apparent in CFU-GM assay (Figure 2 ). This suggests that other pathways can contribute to TKI resistance. G-CSF has been reported to act independently of p-STAT5 in CML cells 31 and is known to activate the Jak-STAT3, 32 Ras/raf/MEK/MAPK 33 and PI3 kinase/Akt pathways 34 , which may have role in TKI resistance. Taken together, our data and the recent findings from other groups 29, 35 suggest that CML leukemic progenitors may not be completely dependent on the BCR-ABL1 oncogene for survival, and that activation of the cytokine-mediated (predominantly GM-CSF/IL-3) JAK-2/STAT-5 pathway may circumvent the need for BCR-ABL1 signaling for the maintenance of cell survival. Thus, signaling through growth factor receptors may not be critical in the presence of fully active Bcr-Abl kinase; however, under the effect of TKIs, progenitors may be rescued through such survival pathway either through autocrine 25, 29, 31, 36 and/or paracrine 29, 37 mechanisms. A critical observation that distinguishes primary CML progenitors from CML cell lines is that short-term intense kinase inhibition commits CD34 þ cells to death only in the absence of cytokines. Thus, our results suggest that a therapeutic strategy based on short-term intense kinase inhibition may have limited success unless critical redundant cytokine-induced survival pathways are also inhibited. We postulate that blocking of cytokine signaling along with short-term intense Bcr-Abl kinase inhibition may provide an effective strategy to eradicate primitive CML cells. þ cells (n ¼ 6) were cultured with 100 nM dasatinib for 30 min (D100ST) in the absence of cytokines. After thorough drug washout, cells were recultured in drug-free media in the presence of 6-GFs (6-GF rescue, 6-GF-R) or GM-CSF (GM-CSF rescue, GM-CSF-R) for the remainder of 72 h. (a) 6-GFs, or GM-CSF supplementation after 30 min of D100ST, rescued 48 and 65% of CML-CD34 þ cells, respectively (b) The magnitude of response varied between patients. CD34 þ cells of same six patients were also cultured with 6-GFs or GM-CSF during and after the short-term culture with 100 nM dasatinib, and these culture conditions are represented as '6-GF' and 'GM-CSF' columns in the figure. In each patient, colonies were normalized to the no-drug control (for each culture condition) and data are presented as mean ± s.e.m.
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